JPRN-UMIN000021143已完成未知
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome - Rituximab to refractory nephrotic syndrome
Fujita Health University School of Medicine, Department of Nephrology0 个研究点目标入组 10 人开始时间: 2016年2月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe hypersensitivity to the component of rituximab or products derived from mouse protein. 2. Positive serology for HBs antigen or HBv-DNA 3. Active infection
研究者
相似试验
未知
2 期
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
已完成
不适用
Rituximab therapy for refractory pemphigusJPRN-jRCTs031180405Funakoshi Takeru20
招募中
不适用
Safety evaluation study about rituximab therapy for refractory pemphiguspemphigusJPRN-UMIN000026004Keio University, School of Medicine20
进行中（未招募）
1 期
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
已完成
2 期
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27